Impact of Gleason pattern 5 on prognosis for newly diagnosed metastatic hormone-sensitive prostate cancer with Gleason score ≥8.
Gleason pattern 5
metastatic hormone-sensitive prostate cancer
metastatic volume
primary Gleason pattern 5
prognosis
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
17
08
2021
accepted:
12
12
2021
pubmed:
19
1
2022
medline:
8
4
2022
entrez:
18
1
2022
Statut:
ppublish
Résumé
We evaluated the impact of Gleason pattern 5 presence on prognosis among de novo metastatic hormone-sensitive prostate cancer patients with a Gleason score ≥8. The data of 559 patients diagnosed as metastatic hormone-sensitive prostate cancer with a Gleason score ≥8, who were initially treated with androgen deprivation therapy from 2008 to 2016, were retrospectively collected. Patients were divided into two groups as high and low volume based on the CHAARTED trial criteria. The median overall survival of the 559 metastatic hormone-sensitive prostate cancer patients with Gleason score ≥8 was 70 months, with a median follow-up period of 36 months. Gleason pattern 5 was confirmed in 341 patients (61.0%), in which primary Gleason pattern 5 was confirmed in 164 patients (29.3%). The number of patients with high metastatic volume group was 363 (64.9%). In total and high metastatic volume groups, hemoglobin and lactate dehydrogenase were significant factors for predicting overall survival, but both Gleason pattern 5 and primary Gleason pattern 5 did not show a statistically significant difference. In the low-volume metastatic group, the median overall survival in patients with or without primary Gleason pattern 5 was 40 and 78 months, respectively. In multivariate analysis, only primary Gleason pattern 5 was an independent predictive factor for overall survival in the low-volume metastatic group (hazard ratio 2.76, 95% confidence interval 1.88-8.67; P = 0.0026). The presence of Gleason pattern 5 was not associated with overall survival in metastatic hormone-sensitive prostate cancer with a Gleason score ≥8. In low-metastatic volume metastatic hormone-sensitive prostate cancer, primary Gleason pattern 5 was a poor prognostic factor, which might show a separate treatment option for this group.
Substances chimiques
Androgen Antagonists
0
Hormones
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
324-331Informations de copyright
© 2022 The Japanese Urological Association.
Références
Frandsen J, Orton A, Shrieve D et al. Risk of death from prostate cancer with and without definitive local therapy when Gleason Pattern 5 is present: a surveillance, epidemiology, and end results analysis. Cureus 2017; 9: e1453.
National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: prostate cancer. [Cited 24 Jul 2021.] Available from URL: https://seer.cancer.gov/startfacts/htmal/prost.html
Damodaran S, Lang JM, Jarrard DF. Targeting metastatic hormone sensitive prostate cancer: chemohormonal therapy and new combinatorial approaches. J. Urol. 2019; 201: 876-85.
Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737-46.
Tsao CK, Oh WK. First-line treatment of hormone-sensitive metastatic prostate cancer: is there a single standard of care? J. Clin. Oncol. 2012; 36: 1060-1.
Soloway MS, Hardeman SW, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
Gravis G, Boher JM, Chen YH et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur. Urol. 2018; 73: 847-55.
Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 2018; 36: 1080-7.
James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 2017; 377: 338-51.
Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019; 20: 686-700.
Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 2019; 381: 13-24.
Hoyle AP, Ali A, James ND et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur. Urol. 2019; 76: 719-28.
Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 2019; 37: 2974-86.
Stroup SP, Moreira DM, Chen Z et al. Biopsy detected Gleason Pattern 5 is associated with recurrence, metastasis and mortality in a cohort of men with high risk prostate cancer. J. Urol. 2017; 198: 1309-15.
Brockman JA, Alanee S, Vickers AJ et al. Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy. Eur. Urol. 2016; 67: 1160-7.
Shiota M, Nakamura M, Yokomizo A et al. Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study. Anticancer. Drugs 2020; 31: 298-303.
Narita S, Hatakeyama S, Takahashi M et al. Clinical outcomes and prognostic factors in patients with newly diagnosed metastatic prostate cancer initially treated with androgen deprivation therapy: a retrospective multicenter study in Japan. Int. J. Clin. Oncol. 2020; 25: 912-20.
Akamatsu S, Kubota M, Uozumi R et al. Development and validation of a novel prognostic model for predicting overall survival in treatment-naïve castration-sensitive metastatic prostate cancer. Eur. Urol. Oncol. 2019; 2: 320-8.
Miyoshi Y, Yasui M, Yoneyama S et al. A novel prognostic model for Japanese patients with newly diagnosed bone-metastatic hormone-naïve prostate cancer. BJUI Compass 2021; 2: 105-14.
Shiota M, Terada N, Saito T et al. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2021; 112: 1524-33.
Rusthoven CG, Carlson JA, Waxweiler TV et al. The prognostic significance of Gleason scores in metastatic prostate cancer. Urol. Oncol. 2014; 32: 707-13.
Miyamoto S, Miyakubo M, Suzuki R et al. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy. Prostate Cancer Prostatic Dis. 2012; 15: 75-86.
Li F, Xiang H, Pang Z et al. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: a meta-analysis. Cancer Med. 2020; 9: 7341-51.
Beer TM, Tangen CM, Bland LB et al. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: a multivariate analysis of Southwest Oncology Group Study 8894. Cancer 2006; 107: 489-96.
Cheng L, Koch MO, Juliar BE et al. The combined percentage of Gleason patterns 4 and 5 is the best predictor of cancer progression after radical prostatectomy. J. Clin. Oncol. 2005; 23: 2911-7.
Tosoian JJ, Gorin MA, Ross AE et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 2017; 14: 15-25.
Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur. Urol. 2014; 65: 1058-66.
Parker CC, James ND, Brawley CD et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 2018; 392: 2353-66.
Halabi S, Kelly WK, Ma H et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J. Clin. Oncol. 2016; 34: 1652-9.